Plerixafor stem cell mobilization in Japanese children: A post‐marketing study

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study

Background Plerixafor is approved in Japan for hematopoietic stem cell mobilization prior to autologous transplant, but limited data are available on the use in children. This study evaluates the safety and effectiveness of plerixafor in Japanese children aged

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatrics international 2022-01, Vol.64 (1), p.e15106-n/a
Hauptverfasser: Goto, Hiroaki, Kanamori, Rie, Nishina, Satoshi, Seto, Takashi
Format: Artikel
Sprache:eng
Schlagworte:
Apheresis
autologous stem cell transplantation
Benzylamines
CD34 antigen
Chemotherapy
Child
Children
Clinical medicine
Cyclams
Fever
Hematopoietic Stem Cell Mobilization - methods
Hematopoietic stem cells
Heterocyclic Compounds - adverse effects
Humans
Japan
Leukocytes (granulocytic)
Marketing
Original
Patients
Pediatrics
plerixafor
post‐marketing surveillance
Safety
Solid tumors
Stem cells
Vomiting
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Plerixafor is approved in Japan for hematopoietic stem cell mobilization prior to autologous transplant, but limited data are available on the use in children. This study evaluates the safety and effectiveness of plerixafor in Japanese children aged
ISSN:1328-8067
1442-200X
DOI:10.1111/ped.15106